Print

Featured Studies Results

A Study of the Drug REC-4881 For Treating People with Advanced Cancers with an APC or AXIN1 Mutation

https://www.facingourrisk.org/research-clinical-trials/study/290/a-study-of-the-drug-rec-4881-for-treating-people-with-advanced-cancers-with-an-apc-or-axin1-mutation

Clinicaltrials.gov identifier:
NCT06005974 (https://clinicaltrials.gov/show/NCT06005974)

Treatment
Treatment study for people with advanced cancer with an APC or AXIN1 mutation


FORCE Survey for People at Increased Risk for Breast or Gynecologic Cancer Due to an Inherited Mutation

https://www.facingourrisk.org/research-clinical-trials/study/287/survey-for-people-at-increased-risk-for-breast-or-gynecologic-cancer-due-to-an-inherited-mutation

Surveys, Registries, Interviews
Survey for people at high risk for breast and gynecologic cancer due to an inherited mutation


Testing the Safety And Action of the Investigational Drug REC-4881 in People With Familial Adenomatous Polyposis (FAP) (TUPELO Study)

https://www.facingourrisk.org/research-clinical-trials/study/288/testing-the-safety-and-action-of-the-investigational-drug-rec-4881-in-people-with-familial-adenomatous-polyposis-fap

Clinicaltrials.gov identifier:
NCT05552755 (https://clinicaltrials.gov/show/NCT05552755)

Prevention
Prevention study for people with an APC mutation and FAP who have had colectomy surgery


Studies for People with ER-Positive, HER2-Negative Advanced or Metastatic Breast Cancer (TACTIVE-U)

https://www.facingourrisk.org/research-clinical-trials/study/279/treatment-studies-for-people-with-er-positive-her2-negative-advanced-or-metastatic-breast-cancer-tactive-u

Treatment
Treatment for ER-positive, HER2-negative metastatic breast cancer


Studies for People With ER-Positive, HER2-Negative Advanced or Metastatic Breast Cancer (VERITAC Studies)

https://www.facingourrisk.org/research-clinical-trials/study/269/studies-for-people-with-er-positive-her2-negative-advanced-or-metastatic-breast-cancer-veritac-studies

Treatment
Treatment studies for ER-positive, HER2-negative metastatic breast cancer


Pancreatic Cancer Early Detection for People at High Risk

https://www.facingourrisk.org/research-clinical-trials/study/227/pancreatic-cancer-early-detection-for-people-at-high-risk

Clinicaltrials.gov identifier:
NCT04970056 (https://clinicaltrials.gov/show/NCT04970056)

Prevention
Registry and biobank for high risk people undergoing pancreatic cancer screening


Cancer Prevention Vaccine (Nous-209) for People with Lynch Syndrome

https://www.facingourrisk.org/research-clinical-trials/study/278/cancer-prevention-vaccine-nous-209-for-people-with-lynch-syndrome

Clinicaltrials.gov identifier:
NCT05078866 (https://clinicaltrials.gov/show/NCT05078866)

Prevention
Prevention study for people with Lynch syndrome


Lynch Syndrome Vaccine Study

https://www.facingourrisk.org/research-clinical-trials/study/273/testing-a-combination-of-vaccines-for-cancer-prevention-in-lynch-syndrome

Clinicaltrials.gov identifier:
NCT05419011 (https://clinicaltrials.gov/show/NCT05419011)

Prevention
Testing A Combination Of Vaccines For Cancer Prevention In Lynch Syndrome


A Study to Compare Two Surgical Procedures in Women with BRCA1 Mutations to Assess Reduced Risk of Ovarian Cancer (SOROCk)

https://www.facingourrisk.org/research-clinical-trials/study/101/a-study-to-compare-two-surgical-procedures-in-women-with-brca1-mutations-to-assess-reduced-risk-of-ovarian-cancer-sorock

Clinicaltrials.gov identifier:
NCT04251052 (https://clinicaltrials.gov/show/NCT04251052)

Prevention
Ovarian cancer prevention for women with a BRCA1 mutation who still have their ovaries


Study of a New Immunotherapy Treatment Called NC410 in People with Different Types of Advanced or Metastatic Cancers

https://www.facingourrisk.org/research-clinical-trials/study/251/study-of-an-immunotherapy-treatment-in-individuals-with-advanced-or-metastatic-solid-tumors

Clinicaltrials.gov identifier:
NCT05572684 (https://clinicaltrials.gov/show/NCT05572684)

Treatment
People with advanced or metastatic colorectal, endometrial, ovarian, stomach, esophageal or other cancers


PROMISE Registry: A Prostate Cancer Registry of Outcomes and Germline Mutations for Improved Survival and Treatment Effectiveness

https://www.facingourrisk.org/research-clinical-trials/study/149/promise-registry-a-prostate-cancer-registry-of-outcomes-and-germline-mutations-for-improved-survival-and-treatment-effectiveness

Clinicaltrials.gov identifier:
NCT04995198 (https://clinicaltrials.gov/show/NCT04995198)

Surveys, Registries, Interviews
A screening registry for people diagnosed with prostate cancer


Combining the Immunotherapy Dostarlimab and PARP Inhibitor Niraparib for Advanced or Metastatic Breast, Ovarian or Pancreatic Cancer with an Inherited or Tumor BRCA Mutation

https://www.facingourrisk.org/research-clinical-trials/study/231/immunotherapy-and-parp-inhibitor-for-advanced-or-metastatic-breast-ovarian-or-pancreatic-cancer-with-a-brca-mutation

Clinicaltrials.gov identifier:
NCT04673448 (https://clinicaltrials.gov/show/NCT04673448)

Treatment
Treatment study for people with advanced breast, ovarian or pancreatic cancer and an inherited or tumor BRCA mutation


Studying a Combination of Three Drugs to Treat Previously Untreated Metastatic Colorectal Cancer which Is MSI-High and Has a BRAF V600E Mutation

https://www.facingourrisk.org/research-clinical-trials/study/252/comparing-three-drugs-in-patients-with-metastatic-colorectal-cancer-who-have-not-had-prior-treatment

Clinicaltrials.gov identifier:
NCT05217446 (https://clinicaltrials.gov/show/NCT05217446)

Treatment
Study for metastatic colorectal cancer that has not yet been treated


Using ctDNA Blood Test for Earlier Detection and Treatment of Recurrence or Spread after Treatment for Stage 3 Colon Cancer

https://www.facingourrisk.org/research-clinical-trials/study/283/using-ctdna-for-earlier-detection-and-treatment-of-recurrence-or-spread-after-treatment-for-stage-3-colon-cancer

Clinicaltrials.gov identifier:
NCT03803553 (https://clinicaltrials.gov/show/NCT03803553)

Treatment
Monitoring and treatment study for people who completed treatment for stage 3 colon cancer


TAPUR Study: Testing FDA Approved Drugs Targeting Tumor Biomarkers in People with Advanced Stage Cancer

https://www.facingourrisk.org/research-clinical-trials/study/262/tapur-study-testing-fda-approved-drugs-targeting-tumor-gene-abnormalities-in-people-with-advanced-stage-cancer

Clinicaltrials.gov identifier:
NCT02693535 (https://clinicaltrials.gov/show/NCT02693535)

Treatment
Cancer treatment study for people with advanced solid tumors


Exploring How People of Caribbean Descent Share Information About Their Genetic Mutations with Family Members

https://www.facingourrisk.org/research-clinical-trials/study/275/exploring-how-people-of-caribbean-descent-share-information-about-their-genetic-mutations-with-their-family-members

Surveys, Registries, Interviews
Survey and interview for people of Caribbean descent who tested positive for a genetic mutation linked to cancer.


Testing a Vaccine for Treating or Preventing Triple-Negative Breast Cancer

https://www.facingourrisk.org/research-clinical-trials/study/285/

Clinicaltrials.gov identifier:
NCT04674306 (https://clinicaltrials.gov/show/NCT04674306)

Treatment
Treatment study for people with stage 2 or 3 triple-negative breast cancer at high risk for recurrence.


Comparing a Combination of Drugs for Treatment of HER2-positive Colorectal Cancer as First Line Treatment in the Metastatic Setting

https://www.facingourrisk.org/research-clinical-trials/study/274/treatment-of-her2-positive-colorectal-cancer-as-first-line-treatment-in-the-metastatic-setting

Clinicaltrials.gov identifier:
NCT05253651 (https://clinicaltrials.gov/show/NCT05253651)

Treatment
People with HER2-positive colorectal cancer who have not yet received treatment in the metastatic setting


Preferences Survey for Women With an Inherited BRCA Mutation and Without a Cancer Diagnosis

https://www.facingourrisk.org/research-clinical-trials/study/239/preferences-survey-for-women-with-an-inherited-brca-mutation-and-without-a-cancer-diagnosis

Surveys, Registries, Interviews
Online survey for women with a BRCA1 or BRCA2 inherited mutation and no personal history of cancer.


Coaching for Family Caregivers of People with Advanced Cancer from Rural and Minority Communities

https://www.facingourrisk.org/research-clinical-trials/study/272/quality-of-life-study-for-caregivers-involving-in-person-or-telephone-coaching-sessions

Clinicaltrials.gov identifier:
NCT04318886 (https://clinicaltrials.gov/show/NCT04318886)

Quality of Life
Quality of life study for caregivers involving in-person or telephone coaching sessions


Study of Colorectal Cancer and Genetics in Hispanic and Latino People (ENLACE Study)

https://www.facingourrisk.org/research-clinical-trials/study/276/study-of-colorectal-cancer-and-genetics-in-hispanic-and-latino-people-enlace-study

Treatment
Hispanic and Latino people diagnosed with colorectal cancer


Testing a Vaccine for Preventing or Treating Triple-Negative Breast Cancer

https://www.facingourrisk.org/research-clinical-trials/study/284/testing-a-vaccine-for-treating-or-preventing-triple-negative-breast-cancer

Clinicaltrials.gov identifier:
NCT04674306 (https://clinicaltrials.gov/show/NCT04674306)

Prevention
Prevention study for people with a BRCA1, BRCA2 or PALB2 inherited mutation who are planning to undergo risk-reducing mastectomy.


Men at High Genetic Risk for Prostate Cancer

https://www.facingourrisk.org/research-clinical-trials/study/72/men-at-high-genetic-risk-for-prostate-cancer

Clinicaltrials.gov identifier:
NCT03805919 (https://clinicaltrials.gov/show/NCT03805919)

Prevention
Prostate screening with MRI for men with Lynch syndrome (MLH1, MSH2, MSH6, PMS2, EPCAM) or a BRCA1, BRCA2, HOXB13, ATM, NBN, TP53, BRIP1, CHEK2, PALB2, RAD51C, RAD51D, or other mutation


Collecting Blood and Stool Samples to Detect Colorectal Cancer or Precancerous Polyps in Lynch Syndrome Patients, CORAL Study

https://www.facingourrisk.org/research-clinical-trials/study/256/early-detection-of-colorectal-cancer-for-people-with-lynch-syndrome

Clinicaltrials.gov identifier:
NCT05410977 (https://clinicaltrials.gov/show/NCT05410977)

Prevention
People with Lynch Syndrome at risk for colon cancer


Study of the PARP inhibitor AZD9574 Alone and Combined with Other Cancer Medicines to Treat People with Advanced Solid Cancers (CERTIS1 Study)

https://www.facingourrisk.org/research-clinical-trials/study/282/study-of-the-parp-inhibitor-azd9574-alone-and-combined-with-other-cancer-medicines-to-treat-people-with-advanced-solid-cancers-certis1-study

Clinicaltrials.gov identifier:
NCT05417594 (https://clinicaltrials.gov/show/NCT05417594)

Treatment
Treatment study for people with advanced breast, ovarian, pancreatic or prostate cancer or gliomas


The WISDOM Study: Women Informed to Screen Depending on Measures of Risk

https://www.facingourrisk.org/research-clinical-trials/study/45/wisdom-study

Clinicaltrials.gov identifier:
NCT02620852 (https://clinicaltrials.gov/show/NCT02620852)

Prevention
Study to Determine if Breast Cancer Screening can be Made Better by Personalizing Each Woman’s Mammogram Schedule


LIVING WELL: A Web-Based Program to Improve Quality of Life in Ovarian Cancer Survivors

https://www.facingourrisk.org/research-clinical-trials/study/270/living-well-a-web-based-program-to-improve-quality-of-life-in-ovarian-cancer-survivors

Clinicaltrials.gov identifier:
NCT04533763 (https://clinicaltrials.gov/show/NCT04533763)

Quality of Life
A research program offering mindfulness, coping, and healthy lifestyle skills for ovarian cancer survivors.


MRI Screening in Men at High Risk of Developing Prostate Cancer

https://www.facingourrisk.org/research-clinical-trials/study/260/screening-in-men-at-high-risk-of-developing-prostate-cancer

Clinicaltrials.gov identifier:
NCT05608694 (https://clinicaltrials.gov/show/NCT05608694)

Prevention
Screening using MRI for men at risk of developing prostate cancer


My Best GI Eating Study

https://www.facingourrisk.org/research-clinical-trials/study/258/my-best-gi-eating-study

Clinicaltrials.gov identifier:
NCT05396846 (https://clinicaltrials.gov/show/NCT05396846)

Prevention
Diet and weight loss study for people who are overweight and at increased risk of colorectal cancer


Helping Latinas Understand Their Risk for Breast Cancer and Get Breast Cancer Care

https://www.facingourrisk.org/research-clinical-trials/study/250/helping-latinas-understand-their-risk-for-breast-cancer-and-get-breast-cancer-care

Clinicaltrials.gov identifier:
NCT05483283 (https://clinicaltrials.gov/show/NCT05483283)

Prevention
Latinas with a high risk of breast cancer


Intimacy and Self-Esteem Among Sexual and Gender Minority Cancer Survivors (RISE-SGM)

https://www.facingourrisk.org/research-clinical-trials/study/265/an-interview-about-intimacy-and-self-esteem-for-sexual-and-gender-minority-cancer-survivors

Surveys, Registries, Interviews
A one-time interview study to explore experiences with sexual functioning, sexual relationships, sexual self-concept, and self-esteem of 18-39-year-old sexual and/or gender minority cancer survivors


Studying People and Families Affected by Li-Fraumeni Syndrome (TP53 Mutation )

https://www.facingourrisk.org/research-clinical-trials/study/267/observing-people-who-have-li-fraumeni-syndrome-tp53-genetic-mutation

Clinicaltrials.gov identifier:
NCT01443468 (https://clinicaltrials.gov/show/NCT01443468)

Surveys, Registries, Interviews
Registry for people with Li-Fraumeni syndrome (LFS) or from LFS families


Registry to Promote Health Equity for People of African Ancestry with Breast or Prostate Cancer

https://www.facingourrisk.org/research-clinical-trials/study/277/registry-to-promote-health-equity-for-people-of-african-ancestry-with-breast-or-prostate-cancer

Clinicaltrials.gov identifier:
NCT05754658 (https://clinicaltrials.gov/show/NCT05754658)

Surveys, Registries, Interviews
This is a registry for people of African ancestry who have breast or prostate cancer


A Surveillance Program for Women at High Risk for Breast Cancer (CAPSBRACA)

https://www.facingourrisk.org/research-clinical-trials/study/271/a-surveillance-program-for-women-at-high-risk-for-breast-cancer-capsbraca

Clinicaltrials.gov identifier:
NCT03729115 (https://clinicaltrials.gov/show/NCT03729115)

Surveys, Registries, Interviews
Screening study for women at risk for breast cancer due to an inherited mutation or other risk factor


Survey For Individuals With A Hereditary Cancer Genetic Testing Result That Was Later Reclassified

https://www.facingourrisk.org/research-clinical-trials/study/261/survey-for-individuals-with-a-hereditary-cancer-genetic-testing-result-that-was-later-reclassified

Prevention
Survey for people whose genetic test results were reclassified


Testing the Drug Obeticholic Acid for Familial Adenomatous Polyposis

https://www.facingourrisk.org/research-clinical-trials/study/289/testing-the-drug-obeticholic-acid-for-familial-adenomatous-polyposis

Clinicaltrials.gov identifier:
NCT05223036 (https://clinicaltrials.gov/show/NCT05223036)

Prevention
Prevention study for people with an APC mutation and FAP or AFAP who have polyps in remaining tissue after colectomy surgery


A Randomized Study of Robotic-Assisted Nipple Sparing Mastectomy vs. Standard Surgery Nipple Sparing Mastectomy for Early Stage Breast Cancer

https://www.facingourrisk.org/research-clinical-trials/study/263/a-randomized-study-of-robotic-assisted-nipple-sparing-mastectomy-vs-open-surgery-nipple-sparing-mastectomy-for-early-stage-breast-cancer

Clinicaltrials.gov identifier:
NCT05720039 (https://clinicaltrials.gov/show/NCT05720039)

Treatment
Nipple sparing mastectomy with reconstruction for women with early-stage breast cancer


Testing a Vaccine for Cancer Prevention in People with a BRCA1 or BRCA2 Mutation

https://www.facingourrisk.org/research-clinical-trials/study/172/testing-a-vaccine-for-cancer-prevention-in-people-with-a-brca1-or-brca2-mutation

Clinicaltrials.gov identifier:
NCT04367675 (https://clinicaltrials.gov/show/NCT04367675)

Prevention
People with a BRCA1 or BRCA2 mutation


Denosumab for Breast Cancer Risk Reduction in Women With an Inherited BRCA1 Mutation (The Breast Cancer Prevention Study)

https://www.facingourrisk.org/research-clinical-trials/study/196/denosumab-for-breast-cancer-risk-reduction-in-women-with-an-inherited-brca1-mutation-the-breast-cancer-prevention-study

Clinicaltrials.gov identifier:
NCT04711109 (https://clinicaltrials.gov/show/NCT04711109)

Prevention
Prevention study enrolling women ages 25-55 with a BRCA1 mutation


Survey about Motivations and Barriers to Talking with Family Members about Inherited Cancer Risk

https://www.facingourrisk.org/research-clinical-trials/study/280/survey-about-goals-of-inherited-cancer-risk-disclosure-in-families-with-an-inherited-gene-mutation

Surveys, Registries, Interviews
Survey for people with an inherited gene mutation


A Study of Targeted Therapies for Patients With Recurrent Endometrial Cancer

https://www.facingourrisk.org/research-clinical-trials/study/245/a-study-of-different-targeted-therapies-for-patients-with-recurrent-or-persistent-endometrial-cancer

Clinicaltrials.gov identifier:
NCT04486352 (https://clinicaltrials.gov/show/NCT04486352)

Treatment
This study is to test the safety and effectiveness of different kinds of targeted therapy with or without atezolizumab (or Tecentriq) in individuals with recurrent endometrial cancer.


A Study Comparing Two Anti-inflammatory Medications Naproxen or Aspirin for Cancer Prevention in Lynch Syndrome

https://www.facingourrisk.org/research-clinical-trials/study/281/studying-the-use-of-naproxen-and-aspirin-for-cancer-prevention-in-people-with-lynch-syndrome

Clinicaltrials.gov identifier:
NCT05411718 (https://clinicaltrials.gov/show/NCT05411718)

Prevention
Prevention study for people with Lynch syndrome


Kindred Study

https://www.facingourrisk.org/research-clinical-trials/study/255/kindred

Surveys, Registries, Interviews
Interviews with African American people who tested positive for a genetic mutation


Testing an Immunotherapy, Pembrolizumab, in Patients With Advanced Solid Tumors

https://www.facingourrisk.org/research-clinical-trials/study/234/testing-an-immunotherapy-in-patients-with-advanced-solid-tumors

Clinicaltrials.gov identifier:
NCT02628067 (https://clinicaltrials.gov/show/NCT02628067)

Treatment
Treatment study for people with advanced cancers


Upright MRI for Prostate Cancer Screening

https://www.facingourrisk.org/research-clinical-trials/study/259/upright-mri-for-prostate-cancer-screening

Clinicaltrials.gov identifier:
NCT03474913 (https://clinicaltrials.gov/show/NCT03474913)

Prevention
Screening for prostate cancer using upright MRI


Comparing Three Drugs as Late-Stage Treatment for Individuals with Metastatic Colorectal Cancer

https://www.facingourrisk.org/research-clinical-trials/study/246/comparing-the-drugs-opdualag-and-stivarga-as-late-stage-treatment-for-individuals-with-metastatic-colorectal-cancer

Clinicaltrials.gov identifier:
NCT05328908 (https://clinicaltrials.gov/show/NCT05328908)

Treatment
treatment study for people with metastatic colorectal cancer


Self -Perception and Intimacy After the Cancer Experience (SPICE)

https://www.facingourrisk.org/research-clinical-trials/study/247/self-perception-and-intimacy-after-the-cancer-experience-spice

Surveys, Registries, Interviews
Online survey for cancer survivors ages 18-39 years old about sexual health


Metastatic Castration Resistant Prostate Cancer Clinical Trial

https://www.facingourrisk.org/research-clinical-trials/study/240/metastatic-castration-resistant-prostate-cancer-clinical-trial

Clinicaltrials.gov identifier:
NCT03460977 (https://clinicaltrials.gov/show/NCT03460977)

Treatment
This clinical trial is studying a potential treatment for men with metastatic castration resistant prostate cancer.


Investigating the Use of Self-Acupressure for Fatigue in Ovarian Cancer Survivors

https://www.facingourrisk.org/research-clinical-trials/study/242/investigating-the-use-of-self-acupressure-for-fatigue-in-ovarian-cancer-survivors

Clinicaltrials.gov identifier:
NCT03763838 (https://clinicaltrials.gov/show/NCT03763838)

Quality of Life
University of Michigan researchers are investigating the use of self-acupressure for fatigue in ovarian cancer survivors.


Survey for Women at High Risk for Breast Cancer on Knowledge and Perspectives about Breast Cancer Risk Factors and Screening

https://www.facingourrisk.org/research-clinical-trials/study/238/survey-for-women-at-high-risk-for-breast-cancer-on-knowledge-and-perspectives-about-breast-cancer-risk-factors-and-screening

Surveys, Registries, Interviews
Online survey for women with an ATM, BARD1, BRCA1, BRCA2, CDH1, CHEK2, PALB2, PTEN, RAD51C, RAD51D, STK11 or TP53 inherited mutation.


Niraparib Before Surgery in Treating Patients With High Risk Localized Prostate Cancer and DNA Damage Response Defects

https://www.facingourrisk.org/research-clinical-trials/study/175/niraparib-before-surgery-in-treating-patients-with-high-risk-localized-prostate-cancer-and-dna-damage-response-defects

Clinicaltrials.gov identifier:
NCT04030559 (https://clinicaltrials.gov/show/NCT04030559)

Treatment
High-risk localized prostate cancer


Testing Immunotherapy Treatments for Recurrent Endometrial Cancer

https://www.facingourrisk.org/research-clinical-trials/study/253/testing-cancer-treatments-in-recurrent-endometrial-cancer

Clinicaltrials.gov identifier:
NCT05112601 (https://clinicaltrials.gov/show/NCT05112601)

Treatment
Treatment study for people with endometrial cancer that has returned


Opening the Conversation

https://www.facingourrisk.org/research-clinical-trials/study/228/opening-the-conversation

Clinicaltrials.gov identifier:
NCT04806724 (https://clinicaltrials.gov/show/NCT04806724)

Quality of Life
Online communication program for breast and gynecologic cancer survivors and their partners


Treating Metastatic Solid Tumors with an Inherited or Acquired Gene Mutation Using the PARP Inhibitor Talazoparib

https://www.facingourrisk.org/research-clinical-trials/study/230/treating-metastatic-solid-tumors-with-an-inherited-or-acquired-gene-mutation-using-the-parp-inhibitor-talazoparib

Clinicaltrials.gov identifier:
NCT04550494 (https://clinicaltrials.gov/show/NCT04550494)

Treatment
Treatment study for people with advanced solid tumors


Combined Pembrolizumab & Quavonlimab (MK-1308A) Versus Other Treatments in People With MSI-High or dMMR Stage IV Colorectal Cancer

https://www.facingourrisk.org/research-clinical-trials/study/181/combined-pembrolizumab-quavonlimab-mk-1308a-versus-other-treatments-in-people-with-msi-high-or-dmmr-stage-iv-colorectal-cancer

Clinicaltrials.gov identifier:
NCT04895722 (https://clinicaltrials.gov/show/NCT04895722)

Treatment
Stage 4 colorectal cancer


Survey for People Diagnosed with Breast Cancer to Provide Feedback on a New Type of Clinical Trial

https://www.facingourrisk.org/research-clinical-trials/study/226/survey-for-people-diagnosed-with-breast-cancer-to-provide-feedback-on-a-new-type-of-clinical-trial

Surveys, Registries, Interviews
Survey for people diagnosed with stage 0 - stage 3 breast cancer


Pancreatic Cancer Screening Study (CAPS5)

https://www.facingourrisk.org/research-clinical-trials/study/222/pancreatic-cancer-screening-studycaps5

Clinicaltrials.gov identifier:
NCT02000089 (https://clinicaltrials.gov/show/NCT02000089)

Prevention
Screening study for people at high risk for pancreatic cancer


Combination ATR inhibitor and PARP Inhibitor in Recurrent Ovarian Cancer (CAPRI)

https://www.facingourrisk.org/research-clinical-trials/study/156/combination-atr-inhibitor-and-parp-inhibitor-in-recurrent-ovarian-cancer-capri

Clinicaltrials.gov identifier:
NCT03462342 (https://clinicaltrials.gov/show/NCT03462342)

Treatment
Recurrent ovarian cancer


Effect of Acupuncture on Memory and Thinking Difficulties after Breast Cancer

https://www.facingourrisk.org/research-clinical-trials/study/219/effect-of-acupuncture-on-memory-and-thinking-difficulties-after-breast-cancer

Clinicaltrials.gov identifier:
NCT04837820 (https://clinicaltrials.gov/show/NCT04837820)

Quality of Life
Acupuncture study for people with memory issues who completed treatment for stage 0-3 breast cancer


Restoring Sensation after DIEP Flap Reconstruction

https://www.facingourrisk.org/research-clinical-trials/study/217/restoring-sensation-after-diep-flap-reconstruction

Clinicaltrials.gov identifier:
NCT04533373 (https://clinicaltrials.gov/show/NCT04533373)

Prevention
Study for people undergoing DIEP flap reconstruction


A Randomized Study of Olaparib or Placebo in Patients with Surgically Removed Pancreatic Cancer who have a BRCA1, BRCA2 or PALB2 Mutation (APOLLO)

https://www.facingourrisk.org/research-clinical-trials/study/140/olaparib-or-placebo-in-patients-with-surgically-removed-pancreatic-cancer-who-have-a-brca1-brca2-or-palb2-mutation

Clinicaltrials.gov identifier:
NCT04858334 (https://clinicaltrials.gov/show/NCT04858334)

Treatment


Effects of Occupational Therapy Telehealth Intervention on Cancer-Related Cognitive Impairment in Breast Cancer Survivors

https://www.facingourrisk.org/research-clinical-trials/study/225/effects-of-occupational-therapy-telehealth-intervention-on-cancer-related-cognitive-impairment-in-breast-cancer-survivors

Clinicaltrials.gov identifier:
NCT05505045 (https://clinicaltrials.gov/show/NCT05505045)

Quality of Life
Telehealth study for breast cancer survivors with memory issues


Tools To Be Fit: Tools to Improve Nutrition and Physical Activity for Cancer Survivors

https://www.facingourrisk.org/research-clinical-trials/study/171/tools-to-be-fit-tools-to-improve-nutrition-and-physical-activity-for-colorectal-cancer-survivors

Clinicaltrials.gov identifier:
NCT05056077 (https://clinicaltrials.gov/show/NCT05056077)

Quality of Life
Bladder, breast, colon, endometrial, kidney (renal cell carcinoma), ovarian, prostate, or rectal cancer


Factors Influencing Disparities in Quality of Life among People of Color Affected by Cancer

https://www.facingourrisk.org/research-clinical-trials/study/223/factors-influencing-disparities-in-quality-of-life-among-people-of-color-affected-by-cancer

Surveys, Registries, Interviews
Survey for people of color who have completed treatment for cancer


Prostate Cancer Genetic Risk Evaluation and Screening Study (PROGRESS)

https://www.facingourrisk.org/research-clinical-trials/study/180/prostate-cancer-genetic-risk-evaluation-and-screening-study-progress

Clinicaltrials.gov identifier:
NCT05129605 (https://clinicaltrials.gov/show/NCT05129605)

Prevention
People at high risk for prostate cancer due to an inherited mutation


NUV-868 Alone and in Combination With PARP Inhibitors in Patients With Advanced Solid Tumors

https://www.facingourrisk.org/research-clinical-trials/study/204/nuv-868-alone-and-in-combination-with-parp-inhibitors-in-patients-with-advanced-solid-tumors

Clinicaltrials.gov identifier:
NCT05252390 (https://clinicaltrials.gov/show/NCT05252390)

Treatment
Treatment study for people with advanced solid tumors, including triple-negative breast, ovarian, pancreatic and prostate cancer


Opening the Conversation Study

https://www.facingourrisk.org/research-clinical-trials/study/214/opening-the-conversation-study

Clinicaltrials.gov identifier:
NCT04806724 (https://clinicaltrials.gov/show/NCT04806724)

Quality of Life
Videoconference sessions that address cancer related concerns for couples


Study of Physical Activity at Home for Relief from Neuropathy Caused by Taxanes in People with Breast Cancer

https://www.facingourrisk.org/research-clinical-trials/study/220/physical-activity-at-home-for-relief-from-neuropathy-caused-by-taxanes-in-people-with-breast-cancer

Clinicaltrials.gov identifier:
NCT04621721 (https://clinicaltrials.gov/show/NCT04621721)

Quality of Life
Quality of life study for breast cancer patients experiencing neuropathy from chemotherapy


Treating Metastatic Prostate Cancer with Chemotherapy or PARP Inhibitor in People with Mutations (COBRA)

https://www.facingourrisk.org/research-clinical-trials/study/210/treating-metastatic-prostate-cancer-with-chemotherapy-or-parp-inhibitor-in-people-with-mutations-cobra

Clinicaltrials.gov identifier:
NCT04038502 (https://clinicaltrials.gov/show/NCT04038502)

Treatment
Treatment study for mCRPC with an inherited or tumor mutation in BARD1, BRCA1, BRCA2, BRIP1, CHEK1, FANCL, PALB2, RAD51B, RAD51C, RAD51D or RAD54L


Risk Reducing Salpingectomy With Delayed Oophorectomy as an Alternative to Risk- Reducing Salpingo-oophorectomy in High Risk-Women (TUBA/WISP II)

https://www.facingourrisk.org/research-clinical-trials/study/205/risk-reducing-salpingectomy-with-delayed-oophorectomy-as-an-alternative-to-risk-reducing-salpingo-oophorectomy-in-high-risk-women

Clinicaltrials.gov identifier:
NCT05287451 (https://clinicaltrials.gov/show/NCT05287451)

Prevention
Prevention study for women at high risk for ovarian cancer


Blood Markers of Early Pancreas Cancer

https://www.facingourrisk.org/research-clinical-trials/study/141/blood-markers-of-early-pancreas-cancer

Clinicaltrials.gov identifier:
NCT03568630 (https://clinicaltrials.gov/show/NCT03568630)

Prevention
Observational study for people with family history of pancreas cancer or an inherited mutation linked to pancreatic cancer risk.


Study of Oral Drug Bazedoxifene Plus Conjugated Estrogens for Treating Hot Flashes in Women at High Risk for Breast Cancer

https://www.facingourrisk.org/research-clinical-trials/study/218/bazedoxifene-plus-conjugated-estrogens-for-hot-flashes-in-women-at-high-risk-for-breast-cancer

Clinicaltrials.gov identifier:
NCT04821141 (https://clinicaltrials.gov/show/NCT04821141)

Quality of Life
Women at high risk for breast cancer due to ATM, CDH1, CHEK2, NBN, NF1, PALB2, PTEN, STK11, P53 or PTEN mutation who have hot flashes


Research Opportunity for Previvors and their Romantic Partners

https://www.facingourrisk.org/research-clinical-trials/study/207/research-opportunity-for-previvors-and-their-romantic-partners

Surveys, Registries, Interviews
Interview for people with inherited mutations who had risk-reducing mastectomy and their partners


Young, Empowered & Strong: Web-Based Symptom Monitoring and Self-Management for Young Adult Breast Cancer Survivors (YES Study)

https://www.facingourrisk.org/research-clinical-trials/study/199/young-empowered-strong-web-based-symptom-monitoring-and-self-management-for-young-adult-breast-cancer-survivors

Clinicaltrials.gov identifier:
NCT04906200 (https://clinicaltrials.gov/show/NCT04906200)

Quality of Life
Women diagnosed with breast cancer between the ages of 15-39


BRCA 1 and 2: Interviews on Genetic Testing and Individual Experiences

https://www.facingourrisk.org/research-clinical-trials/study/169/brca-1-and-2-interviews-on-genetic-testing-and-individual-experiences

Surveys, Registries, Interviews
People with or without cancer who have had or are considering BRCA testing


Cancer Experience Registry

https://www.facingourrisk.org/research-clinical-trials/study/248/cancer-experience-registry

Surveys, Registries, Interviews
Online survey for patients and caregivers focusing on multiple aspects of cancer


SHARON: A Clinical Trial for Metastatic Cancer With an Inherited BRCA or PALB2 Mutation Using Chemotherapy and Patients’ Own Stem Cells

https://www.facingourrisk.org/research-clinical-trials/study/117/sharon-a-clinical-trial-for-metastatic-cancer-with-an-inherited-brca-or-palb2-mutation-using-chemotherapy-and-patients-own-stem-cells

Clinicaltrials.gov identifier:
NCT04150042 (https://clinicaltrials.gov/show/NCT04150042)

Treatment
Advanced pancreatic cancer or stage 4 breast cancer in people with a BRCA1 or BRCA2 mutation


Chemotherapy, Immunotherapy and PARP Inhibitor for the Treatment of Metastatic Aggressive Variant Prostate Cancer

https://www.facingourrisk.org/research-clinical-trials/study/200/chemotherapy-immunotherapy-and-parp-inhibitor-for-the-treatment-of-metastatic-aggressive-variant-prostate-cancer-avpc

Clinicaltrials.gov identifier:
NCT04592237 (https://clinicaltrials.gov/show/NCT04592237)

Treatment
Treatment in people with aggressive metastatic prostate cancer


IGNITE-TX - Identifying Individuals for Genetic Testing for Familial Cancer

https://www.facingourrisk.org/research-clinical-trials/study/266/helping-people-with-a-genetic-mutation-in-brca1-brca2-or-lynch-syndrome-talk-to-their-family-members-about-their-risk-for-cancer-and-find-the-best-way-to-get-family-members-tested

Clinicaltrials.gov identifier:
NCT05677048 (https://clinicaltrials.gov/show/NCT05677048)

Prevention
People with a genetic mutation in BRCA1, BRCA2 or Lynch syndrome who have relatives who have not been tested


All of Us Research Program

https://www.facingourrisk.org/research-clinical-trials/study/197/all-of-us-research-program

Surveys, Registries, Interviews
Anyone age 18 or over


Treating Early-Stage HER2-Negative Breast Cancer with a PARP Inhibitor (Niraparib) and Immunotherapy (Dostarlimab) in People with a BRCA or PALB2 Mutation

https://www.facingourrisk.org/research-clinical-trials/study/158/treating-early-stage-breast-cancer-with-a-parp-inhibitor-niraparib-and-immunotherapy-dostarlimab-in-people-with-a-brca-or-palb2-mutation

Clinicaltrials.gov identifier:
NCT04584255 (https://clinicaltrials.gov/show/NCT04584255)

Treatment
Treatment before surgery for people with early-stage breast cancer & a BRCA1, BRCA2 or PALB2 mutation


Androgen Suppression With Abiraterone, Leuprolide, PARP Inhibitor and Stereotactic Radiotherapy in Prostate Cancer (ASCLEPIuS)

https://www.facingourrisk.org/research-clinical-trials/study/177/androgen-suppression-with-abiraterone-leuprolide-parp-inhibitor-and-stereotactic-radiotherapy-in-prostate-cancer-asclepius

Clinicaltrials.gov identifier:
NCT04194554 (https://clinicaltrials.gov/show/NCT04194554)

Treatment
Newly diagnosed prostate cancer grade group 3-5


Investigational PARP Inhibitor AZD5305 Alone or Combined With Other Anti-cancer Agents in People With Advanced Solid Tumors (PETRA)

https://www.facingourrisk.org/research-clinical-trials/study/176/investigational-parp-inhibitor-azd5305-alone-or-combined-with-other-anti-cancer-agents-in-people-with-advanced-solid-tumors-petra

Clinicaltrials.gov identifier:
NCT04644068 (https://clinicaltrials.gov/show/NCT04644068)

Treatment
Advanced ovarian, breast, prostate or pancreatic cancer


Inherited Cancer Registry (ICARE): Contribute to Research While Staying Informed

https://www.facingourrisk.org/research-clinical-trials/study/195/inherited-cancer-registry-icare-contribute-to-research-while-staying-informed

Clinicaltrials.gov identifier:
NCT03231891 (https://clinicaltrials.gov/show/NCT03231891)

Surveys, Registries, Interviews
People with an inherited mutation or cancer in the family


Adding Pembrolizumab to Olaparib to Treat Pancreatic Cancer in People with an Inherited BRCA Mutation

https://www.facingourrisk.org/research-clinical-trials/study/164/adding-pembrolizumab-to-olaparib-to-treat-pancreatic-cancer-in-people-with-an-inherited-brca-mutation

Clinicaltrials.gov identifier:
NCT04548752 (https://clinicaltrials.gov/show/NCT04548752)

Treatment
Metastatic pancreatic cancer and a BRCA1 or BRCA2 mutation


Retifanlimab (Immunotherapy) Alone or Combined with Other Therapies for Advanced Endometrial Cancer that Progressed on or after Platinum Chemotherapy (POD1UM-204)

https://www.facingourrisk.org/research-clinical-trials/study/165/retifanlimab-alone-or-with-other-agents-for-advanced-endometrial-cancer-that-progressed-with-platinum

Clinicaltrials.gov identifier:
NCT04463771 (https://clinicaltrials.gov/show/NCT04463771)

Treatment
Advanced endometrial cancer


Treatment with ATR Inhibitor for Advanced or Metastatic Solid Tumors

https://www.facingourrisk.org/research-clinical-trials/study/157/treatment-with-atr-inhibitor-for-advanced-or-metastatic-solid-tumors

Clinicaltrials.gov identifier:
NCT04657068 (https://clinicaltrials.gov/show/NCT04657068)

Treatment
Advanced solid tumors


Testing the New Targeted Therapy CYH33 in Combination With the PARP Inhibitor Olaparib in People With Advanced Solid Tumors and DNA Damage Repair Mutations

https://www.facingourrisk.org/research-clinical-trials/study/168/cyh33-in-combination-with-olaparib-in-patients-with-advanced-solid-tumors-and-dna-damage-repair-mutations

Clinicaltrials.gov identifier:
NCT04586335 (https://clinicaltrials.gov/show/NCT04586335)

Treatment
Advanced solid tumors


Nivolumab and Relatlimab in Advanced Mismatch Repair Deficient (dMMR/MSI-High) Cancers Resistant to Prior PD-L1 Inhibitor

https://www.facingourrisk.org/research-clinical-trials/study/151/nivolumab-and-relatlimab-in-advanced-msi-h-cancers-resistant-to-prior-pd-l1-inhibitor

Clinicaltrials.gov identifier:
NCT03607890 (https://clinicaltrials.gov/show/NCT03607890)

Treatment
Solid tumors that are MSI-High and resistant to prior immunotherapy


Atorvastatin ± Aspirin for Colorectal Cancer Prevention for People with Lynch Syndrome

https://www.facingourrisk.org/research-clinical-trials/study/144/atorvastatin-aspirin-for-colorectal-cancer-prevention-for-people-with-lynch-syndrome

Clinicaltrials.gov identifier:
NCT04379999 (https://clinicaltrials.gov/show/NCT04379999)

Prevention


Developing a Test for the Detection of Ovarian Cancer

https://www.facingourrisk.org/research-clinical-trials/study/137/developing-a-test-for-the-detection-of-ovarian-cancer

Clinicaltrials.gov identifier:
NCT04794322 (https://clinicaltrials.gov/show/NCT04794322)

Prevention


Chemotherapy, Bevacizumab, and/or Atezolizumab for Patients With Deficient DNA Mismatch Repair (dMMR or MSI-H) Metastatic Colorectal Cancer, the COMMIT Study

https://www.facingourrisk.org/research-clinical-trials/study/126/chemotherapy-bevacizumab-andor-atezolizumab-for-dmmr-msi-h-metastatic-colorectal-cancer-commit-study

Clinicaltrials.gov identifier:
NCT02997228 (https://clinicaltrials.gov/show/NCT02997228)

Treatment


Preliminary Evaluation of Screening for Pancreatic Cancer in Patients with an Inherited Genetic Risk Due to a BRCA1, BRCA2, PALB2 or ATM Mutation

https://www.facingourrisk.org/research-clinical-trials/study/121/screening-for-pancreatic-cancer-in-patients-with-an-inherited-brca1-brca2-palb2-or-atm-mutation

Clinicaltrials.gov identifier:
NCT02478892 (https://clinicaltrials.gov/show/NCT02478892)

Prevention


Olaparib in Treating Patients With Metastatic Biliary Tract Cancer With Aberrant DNA Repair Gene Mutations

https://www.facingourrisk.org/research-clinical-trials/study/129/olaparib-in-treating-patients-with-metastatic-biliary-tract-cancer-with-aberrant-dna-repair-gene-mutations

Clinicaltrials.gov identifier:
NCT04042831 (https://clinicaltrials.gov/show/NCT04042831)

Treatment


Validating a Blood Test for Early Ovarian Cancer Detection in High-risk Women and Families: MicroRNA Detection Study (MiDE)

https://www.facingourrisk.org/research-clinical-trials/study/138/validating-a-blood-test-for-early-ovarian-cancer-detection-in-high-risk-women-and-families

Prevention
Screening study for women with a BRCA1, BRCA2, BRIP1, PALB2, RAD51C, RAD51D, PMS2, MLH1, MSH2, MSH6, or EPCAM mutation


A Study of Nivolumab, Nivolumab Plus Ipilimumab, or Investigator's Choice Chemotherapy for the Treatment of Participants With Deficient Mismatch Repair (dMMR)/Microsatellite Instability High (MSI-H) Metastatic Colorectal Cancer (mCRC) (CheckMate 8HW)

https://www.facingourrisk.org/research-clinical-trials/study/112/nivolumab-nivolumab-plus-ipilimumab-or-chemotherapy-for-microsatellite-instability-high-msi-h-metastatic-colorectal-cancer-checkmate-8hw

Clinicaltrials.gov identifier:
NCT04008030 (https://clinicaltrials.gov/show/NCT04008030)

Treatment
People with metastatic colorectal cancer that is MSI-High


Pembrolizumab and Olaparib for People With Metastatic Pancreatic Cancer with Homologous Recombination Deficiency or Exceptional Response to Platinum Chemotherapy

https://www.facingourrisk.org/research-clinical-trials/study/127/pembrolizumab-and-olaparib-for-metastatic-pancreatic-cancer-with-homologous-recombination-deficiency-or-exceptional-response-to-platinum-chemotherapy

Clinicaltrials.gov identifier:
NCT04666740 (https://clinicaltrials.gov/show/NCT04666740)

Treatment


A Survey on Options for Managing Cancer Risk Among Women with a BRCA1 or BRCA2 Mutation

https://www.facingourrisk.org/research-clinical-trials/study/119/a-survey-on-options-for-managing-cancer-risk-among-women-with-a-brca1-or-brca2-mutation

Surveys, Registries, Interviews


Serum Biomarkers to Characterize the Effects of Therapy on Ovarian Reserve in Premenopausal Women With Early-stage Breast Cancer or BRCA Mutations

https://www.facingourrisk.org/research-clinical-trials/study/109/blood-tests-to-measure-ovarian-reserves-in-women-with-a-brca-mutation-or-women-treated-for-early-stage-breast-cancer

Clinicaltrials.gov identifier:
NCT00823654 (https://clinicaltrials.gov/show/NCT00823654)

Prevention


A Phase 2 Study of Olaparib Monotherapy in Metastatic Breast Cancer Patients with Germline or Somatic Mutations in DNA Repair Genes (Olaparib Expanded)

https://www.facingourrisk.org/research-clinical-trials/study/68/olaparib-expanded-treating-metastatic-breast-cancer-in-people-without-gbrca-mutations

Clinicaltrials.gov identifier:
NCT03344965 (https://clinicaltrials.gov/show/NCT03344965)

Treatment


The Risk Factor Analysis of Hereditary Breast and Ovarian Cancer In Women with BRCA1, BRCA2 or PALB2 Mutations

https://www.facingourrisk.org/research-clinical-trials/study/120/the-risk-factor-analysis-of-hereditary-breast-and-ovarian-cancer-in-women-with-brca1-brca2-or-palb2-mutations

Surveys, Registries, Interviews


Diagnosis of Breast Cancer in Young Women - Share Your Story

https://www.facingourrisk.org/research-clinical-trials/study/113/diagnosis-of-breast-cancer-in-young-women-share-your-story

Surveys, Registries, Interviews


Talazoparib for People with Metastatic Breast Cancer Who Have Acquired (Somatic) BRCA Mutations

https://www.facingourrisk.org/research-clinical-trials/study/100/talazoparib-for-people-with-metastatic-breast-cancer-who-have-acquired-somatic-brca-mutations

Clinicaltrials.gov identifier:
NCT03990896 (https://clinicaltrials.gov/show/NCT03990896)

Treatment


A Randomized Study of an eHealth Delivery Alternative for Cancer Genetic Testing for Hereditary Predisposition in Metastatic Breast, Ovarian, Prostate and Pancreatic Cancer Patients

https://www.facingourrisk.org/research-clinical-trials/study/102/a-randomized-study-of-an-ehealth-delivery-alternative-for-cancer-genetic-testing-for-hereditary-predisposition-in-metastatic-breast-ovarian-prostate-and-pancreatic-cancer-patients-e-reach

Clinicaltrials.gov identifier:
NCT04353973 (https://clinicaltrials.gov/show/NCT04353973)

Treatment


Metastatic Prostate Cancer Project

https://www.facingourrisk.org/research-clinical-trials/study/70/metastatic-prostate-cancer-project

Surveys, Registries, Interviews


The Metastatic Breast Cancer Project

https://www.facingourrisk.org/research-clinical-trials/study/60/the-metastatic-breast-cancer-project

Surveys, Registries, Interviews


A Pancreatic Cancer Screening Study for High Risk Individuals

https://www.facingourrisk.org/research-clinical-trials/study/95/pancreatic-cancer-screening-study-for-high-risk-people

Clinicaltrials.gov identifier:
NCT03250078 (https://clinicaltrials.gov/show/NCT03250078)

Prevention


RANKL Inhibition With Denosumab on Mammographic Density in Premenopausal Women With Dense Breasts (TRIDENT)

https://www.facingourrisk.org/research-clinical-trials/study/93/denosumab-and-mammographic-density-in-premenopausal-women-with-dense-breasts-trident

Clinicaltrials.gov identifier:
NCT04067726 (https://clinicaltrials.gov/show/NCT04067726)

Prevention


Connect My Variant

https://www.facingourrisk.org/research-clinical-trials/study/90/connect-my-variant

Surveys, Registries, Interviews


Genomic Services Research Program Study for People with Unexpected Genetic Results

https://www.facingourrisk.org/research-clinical-trials/study/89/study-for-people-with-unexpected-genetic-results

Clinicaltrials.gov identifier:
NCT02595957 (https://clinicaltrials.gov/show/NCT02595957)

Prevention


Talking to Employers and Medical Staff About Breast Cancer Treatment and Your Job (TEAMWork Study)

https://www.facingourrisk.org/research-clinical-trials/study/86/talking-to-employers-and-medical-staff-about-breast-cancer-treatment-and-your-job

Clinicaltrials.gov identifier:
NCT03572374 (https://clinicaltrials.gov/show/NCT03572374)

Quality of Life


Breast Cancer Treatment in Women with PALB2 Mutations

https://www.facingourrisk.org/research-clinical-trials/study/85/breast-cancer-treatment-in-women-with-palb2-mutations

Surveys, Registries, Interviews


Energetics and Lifestyle in Inherited Syndromes (ELLIE’s Study)

https://www.facingourrisk.org/research-clinical-trials/study/84/ellies-project

Quality of Life


Pragmatic Randomized Trial of Proton vs. Photon Therapy for Patients with Non-Metastatic Breast Cancer Receiving Comprehensive nodal Radiation: A Radiotherapy Comparative Effectiveness Trial

https://www.facingourrisk.org/research-clinical-trials/study/56/radcomp-a-study-at-the-heart-of-breast-cancer-treatment

Clinicaltrials.gov identifier:
NCT02603341 (https://clinicaltrials.gov/show/NCT02603341)

Treatment


Identification and Analysis of Families With Genetic Susceptibility To Cancer Registry

https://www.facingourrisk.org/research-clinical-trials/study/33/identification-and-analysis-of-families-with-genetic-susceptibility-to-cancer-registry

Surveys, Registries, Interviews


Pancreatic Cancer Early Detection Program

https://www.facingourrisk.org/research-clinical-trials/study/20/pancreatic-cancer-early-detection

Clinicaltrials.gov identifier:
NCT02206360 (https://clinicaltrials.gov/show/NCT02206360)

Prevention


About FORCE

FORCE is a national nonprofit organization, established in 1999. Our mission is to improve the lives of individuals and families affected by adult hereditary cancers.